Allergen-specific Immunotherapy in Atopic Eczema

Ring J. Allergy in Practice. Berlin: Springer; 2005. Rajka G. Essential aspects of atopic dermatitis. Berlin: Springer; 1989. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;114:146–8. Leung DYM, Rhodes AR, Geha RS, et al. Atopic dermatitis (atopic eczema). In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in General Medicine. 4th ed. New York: McGraw Hill; 1993. p. 1543–63. Morren MA, Przybilla B, Bamelis M, et al. Atopic dermatitis: triggering factors. J Am Acad Dermatol. 1994;31:467–73. Fukuda H, Imayama S, Okada T. Mite-free room (MFR) for the management of atopic dermatitis. Jpn J Allergol. 1991;40:626–32. Lau S, Ehnert B, Cremer B, et al. Häusliche Milbenallergenreduktion bei spezifisch sensibilisierten Patienten mit atopischem Ekzem. Allergo J. 1995;4:432–5. Sanda T, Yasue T, Oohashi M, Yasue A. Effectiveness of house dust-mite allergen avoidance with atopic dermatitis. J Allergy Clin Immunol. 1992;89:653–7. Tan B, Weald D, Strickland I, Friedman P. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996;347:15–8. Maurer D, Ebner C, Reininger B, et al. The high affinity IgE receptor mediates IgE-dependent allergen presentation. J Immunol. 1995;154:6285–90. Gondo A, Saeki N, Tokuda Y. Challenge reactions in atopic dermatitis after percutaneous entry of mite antigen. Br J Dermatol. 1986;115:485–93. Bieber T. FCeRI on human Langerhans cells: a receptor in search of new functions. Immunol Today. 1994;15:52–3. Bieber T, de la Salle C, Wollenberg A, et al. Constitutive expression of the high affinity receptor for IgE (FCeR1) on human Langerhans-cells. J Exp Med. 1992;175:1285–90. Tanaka Y, Anan S, Yoshida H. Immunohistochemical studies in mite antigen-induced patch test sites in atopic dermatitis. J Derm Science. 1990;1:361–8. Ramb-Lindhauer CH, Feldmann A, Rotte M, Neumann CH. Characterization of grass pollen reactive T-cell lines derived from lesional atopic skin. Arch Dermatol Res. 1991;283:71–6. van Reijsen FC, Bruijnzeel-Koomen CAFM, Kalthoff FS, et al. Skin-derived aeroallergen-specific T-cell clones of TH2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol. 1992;90:184–92. Adinoff A, Tellez P, Clark R. Atopic dermatitis and aeroallergen contact sensitivity. J Allergy Clin Immunol. 1988;81:736–42. Maeda K, Yamamoto K, Tanaka Y, et al. House dust mite (HDM) antigen in naturally occurring lesions of atopic dermatitis (AD): The relationship between HDM antigen in the skin and HDM antigen-specific IgE antibody. J Derm Science. 1992;3:73–7. Mitchell E, Chapman M, Pope F, et al. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet. 1982;I:127–30. Darsow U, Vieluf D, Ring J. Atopy patch test with different vehicles and allergen concentrations—an approach to standardization. J Allergy Clin Immunol. 1995;95:677–84. Darsow U, Vieluf D, Ring J. The atopy patch test: an increased rate of reactivity in patients who have an air-exposed pattern of atopic eczema. Br J Dermatol. 1996;135:182–6. Darsow U, Behrendt H, Ring J. Gramineae pollen as trigger factors of atopic eczema: evaluation of diagnostic measures using the atopy patch test. Br J Dermatol. 1997;137:201–7. Darsow U, Vieluf D, Berg B, et al. Dose response study of atopy patch test in children with atopic eczema. Pediatr Asthma Allergy Immunol. 1999;13:115–22. Darsow U, Vieluf D. Ring J for the APT study group: evaluating the relevance of aeroallergen sensitization in atopic eczema using the tool “atopy patch test”: a randomized, double-blind multicenter study. J Am Acad Dermatol. 1999;40:187–93. Fuchs E, Schadewaldt H. Die Einführung der Hyposensibilisierung in die Heufiebertherapie durch Leonard Noon (1878–1913) und John Freemann (1877–1962) im Jahre 1911. Allergo J. 1996;5:298–300. Elliot JR, Middleton MD, Charles E, Reed MD (eds.). Allergy: Principles and Practice. Mosby, St. Louis, 4th edition, 1993. Karl S, Ring J. Pro and contra of specific hyposensitization. Eur J Dermatol. 1999;9:325–31. Ring J. Spezifische Hyposensibilisierung bei atopischem Ekzem? Allergo J. 1993;2:1–2. Ring J, Przybilla B, Bongardts J. Safety of hyposensitization. In: Cortada Macias JM, editor. Proc Annual Meeting of the EAACI 1987. Madrid: Abelló; 1987. p. 130–8. Malling HJ, Weeke B. Immunotherapy. Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 1993;48 Suppl 14:9–35. Willemse A, van den Brom W, Rijnberk A. Effect of hyposensitization on atopic dermatitis in dogs. J Am Vet Med Assoc. 1984;184:1277–80. Saurat JH. Specific hyposensitization for atopic dermatitis: a new era? Dermatologica. 1991;182:71–2. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol. 1982;107:597–602. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22:440–6. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy. 1974;32:321–30. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978;2:912–5. Zachariae H, Cramers M, Herlin T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl. 1985;114:48–54. Galli E, Chini L, Nardi S, et al. Use of specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol. 1994;22:18–22. Mosca M, Albani-Rocchetti G, Vignini MA, et al. La vaccinoterapia sub-linguale nella dermatite atopica. G Ital Dermatol Venereol. 1993;128:79–83. Zwacka G, Glaser S, Rieger B. Therapeutische Erfahrungen mit Pangramin-SLIT im Vergleich zu einer subkutanen Immuntherapie und zur symptomatischen medikamentösen Behandlung bei Kindern mit Asthma bronchiale, Rhinokonjunktivitis und atopischer Dermatitis. Allergologie. 1996;19:580–92. Mastrandrea F. Immunotherapy in atopic dermatitis. Exp Opin Invest Drugs. 2001;10:1–15. Mastrandrea F, Serio G, Minelli M. Specific sub-lingual immunotherapy in atopic dermatitis. Results of a 6-year follow up of 35 consecutive patients. Allergol Immunopathol. 2000;28:54–62. Noh G, Lee KJ. Pilot study of IFN-gamma-induced specific hyposensitization for house dust mites in atopic dermatitis: IFN-gamma-induced immune deviation as a new therapeutic concept for atopic dermatitis. Cytokine. 2000;12:472–6. Leroy BP, Lachapelle JM, Somville MM, et al. Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis. Dermatologica. 1991;182:98–106. Leroy BP, Boden G, Lachapelle JM, et al. A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study. Am Acad Dermatol. 1993;28:232–9. Werfel T, Breuer K, Ruéff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006;61:202–5. Silny W, Czarnecka-Operacz M. Spezifische Immuntherapie bei der Behandlung von Patienten mit atopischer Dermatitis. Ergebnisse einer placebokontrollierten Doppelblindstudie. Allergologie. 2006;29:171–83. Bousquet J, Lockey RF, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;53 Suppl 44:42. Kühr J, Brauburger J, Zielen S, he Omalizumab Rhinitis Study Group, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:274–80. Bussmann C, Böckenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006;118:1292–8. Di Prisco de Fuenmayor MC, Champion RH. Specific hyposensitization in atopic dermatitis. Br J Dermatol. 1979;101:697–700. Chait I, Allkins V. Remission of life-long atopic dermatitis after hyposensitisation to house dust mite. Practitioner. 1985;229:609–12. Seidenari S, Mosca M, Taglietti M, et al. Specific hyposensitization in atopic dermatitis. Dermatologica. 1986;172:229. Heijer A. Hyposensitization with aeroallergens in atopic eczema. Allergo J. 1993;2:3–7. Pacor ML, Biasi D, Maleknia T. The efficacy of long-term specific immunotherapy for Dermatophagoides pteronyssinus in patients with atopic dermatitis. Recenti Prog Med. 1994;85:273–7. Michils A, Farber CM, Van Vooren JP, et al. Sustained benefit of interferon-alpha therapy and oral hyposensitization in severe atopic dermatitis. Br J Dermatol. 1994;130:134–5. Trofimowicz A, Rzepecka E, Hofman J. Clinical effects of specific immunotherapy in children with atopic dermatitis. Rocz Akad Med Bialymst. 1995;40:414–22. Grewe M. Hyposensibilisierung bei atopischem Ekzem. Allergo J. 2000;9:351–3. Petrova SIu, Berzhets VM, Al’banova VI, et al. Immunotherapy in the complex treatment of patients with atopic dermatitis with sensitization to house dust mites. Zh Mikrobiol Epidemiol Immunobiol. 2001;1:33–6. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164–70. Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy. 2007;37:1277–85. Cadario G, Galluccio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007;23:2503–6. Nahm DH, Lee ES, Park HJ, et al. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. Int Arch Allergy Immunol. 2008;146:235–40.